Context Therapeutics Inc. (CNTX) — 8-K Filings

8-K Filings (20)

• Context Therapeutics Files 8-K with Regulatory Disclosures — Apr 2, 2026 Risk: low
  On April 2, 2026, Context Therapeutics Inc. filed an 8-K report detailing events under Regulation FD Disclosure, Other Events, and Financial Statements and Exhi
• Context Therapeutics Files 8-K — Oct 24, 2025 Risk: low
  Context Therapeutics Inc. filed an 8-K on October 24, 2025, reporting on a material definitive agreement and other events. The filing also includes financial st
• Context Therapeutics Files 8-K Under 'Other Events' — Oct 20, 2025 Risk: medium
  Context Therapeutics Inc. filed an 8-K on October 20, 2025, reporting an event on October 17, 2025. The filing is categorized under 'Other Events' and provides
• Context Therapeutics Faces Delisting Notice — Sep 2, 2025 Risk: high
  Context Therapeutics Inc. filed an 8-K on August 28, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The company, incorpor
• Context Therapeutics Inc. Files 8-K on Security Holder Vote — Jun 12, 2025 Risk: low
  Context Therapeutics Inc. filed an 8-K on June 12, 2025, to report on the submission of matters to a vote of its security holders. The filing indicates that a v
• Context Therapeutics Inc. Files 8-K — Jun 2, 2025 Risk: low
  Context Therapeutics Inc. filed an 8-K on June 2, 2025, reporting on other events and financial statements. The filing details the company's corporate structure
• Context Therapeutics Inc. Files 8-K — Apr 9, 2025 Risk: low
  Context Therapeutics Inc. filed an 8-K on April 9, 2025, reporting on various events including Regulation FD disclosures, other events, and financial statements
• Context Therapeutics Faces Delisting Concerns — Feb 28, 2025 Risk: high
  Context Therapeutics Inc. filed an 8-K on February 28, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The fil
• Context Therapeutics Inc. Files 8-K — Jan 14, 2025 Risk: low
  Context Therapeutics Inc. filed an 8-K on January 14, 2025, reporting on various events and financial statements. The filing indicates the company's principal e
• Context Therapeutics Inc. Files 8-K: Board & Compensation Updates — Jan 13, 2025 Risk: low
  Context Therapeutics Inc. announced on January 10, 2025, changes in its board of directors and executive compensation arrangements. The filing also includes inf
• Context Therapeutics Files 8-K — Dec 23, 2024 Risk: low
  Context Therapeutics Inc. filed an 8-K on December 23, 2024, to report other events. The filing does not contain specific details about the nature of these even
• Context Therapeutics Inc. Files 8-K: Material Agreement Announced — Dec 2, 2024 Risk: medium
  Context Therapeutics Inc. announced on December 2, 2024, that it entered into a material definitive agreement. The company also disclosed information related to
• Context Therapeutics Files 8-K: Material Agreement & Disclosures — Sep 23, 2024 Risk: medium
  On September 23, 2024, Context Therapeutics Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes information on Regulati
• Context Therapeutics Files 8-K — Sep 17, 2024 Risk: low
  Context Therapeutics Inc. filed an 8-K on September 17, 2024, reporting on matters submitted to a vote of security holders and financial statements. The company
• Context Therapeutics Appoints New Director — Sep 4, 2024 Risk: low
  Context Therapeutics Inc. announced on September 4, 2024, a change in its board of directors. Dr. Jonathan T. Raper has been appointed as a new director, effect
• Context Therapeutics Enters Material Definitive Agreement — Jul 10, 2024 Risk: medium
  Context Therapeutics Inc. announced on July 9, 2024, that it entered into a material definitive agreement. The company also disclosed information related to Reg
• Context Therapeutics Inc. Files 8-K on Shareholder Votes — Jun 14, 2024 Risk: low
  Context Therapeutics Inc. filed an 8-K on June 14, 2024, reporting on matters submitted to a vote of security holders as of June 13, 2024. The filing details th
• Context Therapeutics Files 8-K: Material Agreement & Equity Sales — May 2, 2024 Risk: medium
  Context Therapeutics Inc. announced on May 1, 2024, that it entered into a material definitive agreement. The company also disclosed unregistered sales of equit
• Context Therapeutics Files 8-K with Corporate Updates — Apr 1, 2024 Risk: low
  Context Therapeutics Inc. filed an 8-K on April 1, 2024, reporting on various events. The filing includes financial statements and exhibits, and details the com
• Context Therapeutics Files 8-K: Material Agreement & Reg FD — Mar 6, 2024 Risk: low
  Context Therapeutics Inc. filed an 8-K on February 29, 2024, reporting a material definitive agreement and a Regulation FD disclosure. The filing details are as

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX